Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Change from baseline in Systolic Blood Pressure (SBP)

Time frame: Up to Day 78

Change from baseline in Diastolic Blood Pressure (DBP)

Time frame: Up to Day 78

Change from baseline in Mean Arterial Pressure (MAP)

Time frame: Baseline to Day 4

Change from baseline in Pulse Pressure (PP)

Time frame: Baseline to Day 4

Change from baseline in Heart Rate (HR)

Time frame: Up to Day 78

Change from baseline in Stroke Volume (SV)

Time frame: Baseline to Day 4

Maximum change from baseline in SBP across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Maximum change from baseline in DBP across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Maximum change from baseline in MAP across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Maximum change from baseline in PP across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Maximum change from baseline in HR across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Maximum change from baseline in SV across the first 24 hours postdose

Time frame: Baseline to Day 2 (24-hours post dose)

Change from baseline in the 24-hour mean SBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Baseline 24-hour mean SBP is measured from 0 to 24 hours pre-dose

Time frame: Baseline to 24 hours postdose, 24 hours to 48 hours postdose, 48 hours to 72 hours postdose

Change from baseline in the 24-hour mean DBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Baseline 24-hour mean DBP is measured from 0 to 24 hours pre-dose

Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Change from baseline in the 24-hour mean MAP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Baseline 24-hour mean MAP is measured from 0 to 24 hours pre-dose

Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Change from baseline in the 24-hour mean PP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Baseline 24-hour mean PP is measured from 0 to 24 hours pre-dose

Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Change from baseline in the 24-hour mean HR measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Baseline 24-hour mean HR is measured from 0 to 24 hours pre-dose

Time frame: Baseline to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose

Concentrations of REGN5381 over time

Time frame: Up to Day 78

Number of subjects who develop anti-drug antibodies (ADA) and titers

Time frame: Up to Day 78

Percentage of subjects who develop anti-drug antibodies (ADA) and titers

Time frame: Up to Day 78